Clinical Scorecard: CDC flags neurologic symptoms after unapproved botulinum toxin injections
At a Glance
| Category | Detail |
|---|---|
| Condition | Neurologic symptoms reported after botulinum neurotoxin injections |
| Key Mechanisms | Possible explanations included unknown product concentration, contamination, or improper preparation, administration, or storage; the investigation did not determine a cause. |
| Target Population | Patients receiving botulinum neurotoxin injections, particularly from unapproved products or unauthorized suppliers |
| Care Setting | Medical spa injection practice investigated by public health authorities |
Key Highlights
- Three women reported neurologic symptoms after receiving the same unapproved botulinum neurotoxin product at a Colorado medical spa.
- Reported symptoms included dysphonia, headache, blurred vision, limb numbness or weakness, neck stiffness, and dyspnea.
- All three women recovered without hospitalization; one sought outpatient medical care.
- The investigation found injection safety violations involving product sourcing, diluent, vial use, temperature monitoring, and beyond-use dates.
- The implicated product lot was unavailable for testing, and investigators did not establish the cause of the symptoms.
Guideline-Based Recommendations
Diagnosis
- Assess for neurologic symptoms following botulinum neurotoxin injections; reported symptoms in this investigation included dysphonia, blurred vision, dyspnea, headache, sensory symptoms, and muscle weakness.
Management
- Do not purchase or administer unapproved botulinum neurotoxin products from unauthorized suppliers.
- Report adverse events following botulinum neurotoxin injections through FDA MedWatch.
Monitoring & Follow-up
- Maintain appropriate temperature monitoring and observe product storage and beyond-use dates.
- Use single-dose vials for one patient, consistent with the safety violations identified in the investigation.
Risks
- The investigation identified possible risks related to unknown product concentration, contamination, and improper preparation, administration, or storage; it did not determine which, if any, caused the reported symptoms.
Patient & Prescribing Data
Three women received injections from the same product lot in the upper brow, glabella, or upper lip; reported doses were 24, 3, and 10 units.
All three reported symptoms after treatment and recovered without hospitalization. None knew the product was not FDA-approved.
Clinical Best Practices
- Avoid purchasing or administering unapproved products from unauthorized suppliers.
- Follow safe product preparation, administration, storage, and vial-use practices.
- Report adverse events following botulinum neurotoxin injections through FDA MedWatch.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
